- Article
- Source: Campus Sanofi
- 23 Oct 2023
T1DM - Meta-Analysis
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Hero/header-15.jpg/jcr:content/header-15.jpg)
Prescribing Information Toujeo (insulin glargine 300 units/mL)
Prescribing Information Lantus (insulin glargine 100 units/mL)
![toujeo logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Image/toujeo-content-page-logo2--2-.jpg/jcr:content/toujeo-content-page-logo2%20(2).jpg)
Ask us your questions about our products, patient materials or organising a meeting.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Image/T1_Meta_updated_nov22.jpg0/jcr:content/T1_Meta_updated_nov22.jpg)
T1-Meta Analysis
Download this clinical summary to read about the benefits of Toujeo® in this post-hoc meta-analysis of three Edition 6 month, phase III, randomised trials. The study aimed to explore the risk of hypoglycaemia with Toujeo® vs insulin glargine 100U/mL in a broad pool of people with T1DM including children over the age of 6.
MAT-XU-2205629 (v5.0) Date of Preparation: October 2023